GPC3-TARGETED THERAPEUTIC AGENT FOR ADMINISTRATION TO PATIENTS FOR WHOM GPC3-TARGETED THERAPEUTIC AGENT THERAPY IS EFFECTIVE

ABSTRACT

Disclosed is a method for determining the efficacy of a GPC3-targeted therapeutic agent therapy for a patient or against a cancer in the patient, prior to receiving GPC3-targeted therapeutic agent therapy, or for determining whether to continue GPC3-targeted therapeutic agent therapy for a patient. The method includes: measuring the number of immunocytes or the quantity of molecules expressed on said immunocytes in a biological sample isolated from a patient prior to receiving GPC3-targeted therapeutic agent therapy and/or a patient having received GPC3-targeted therapeutic agent therapy; and determining the GPC3-targeted therapeutic agent therapy to be effective or determining that the GPC3-targeted therapeutic agent therapy is to be continued when the number or immunocytes or the quantity of molecules expressed is a predetermined value. Also disclosed is a GPC3-targeted therapeutic agent or drug formulation to be administrated to a patient for whom GPC3-targeted therapeutic agent therapy has been determined effective, or for whom it has been determined to continue GPC3-targeted therapeutic agent therapy.

No suitable figures.